The firm did not disclose how many shares it planned to sell or how much money it expects to raise.
The firm plans to release an upgrade that will improve read lengths and throughput, with an eye toward being a player in the population sequencing market.
PacBio's revenues increased to $21.6 million, but missed analysts average estimate of $23.8 million.
The Beijing-based firm said it will use the funding for research and development, to obtain additional intellectual property, and to pursue its strategic goals.
Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.
With FALCON-Phase, investigators used PacBio long reads and Hi-C data from Phase Genomics to assemble a haplotype-phased, diploid genome for a hybrid bull.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
CBS This Morning highlights recent Medicare fraud involving offers of genetic testing.
Researchers find that many cancer drugs in development don't work quite how their developers thought they did, as Discover's D-brief blog reports.
Mariya Gabriel, a Bulgarian politician, is to be the next European Union research commissioner, according to Science.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.